CRA’s Life Sciences consultants were retained by a generic pharmaceutical manufacturer to assess potential damages exposure, should the manufacturer launch prior to the conclusion of patent litigation. The analysis examined expected generic uptake and entry scenarios, helping the generic manufacturer to decide whether to launch “at risk.” Factors were considered such as first-mover advantage from earlier entry and the price impacts from the entry of subsequent manufacturers. CRA also considered multiple damages theories, including price erosion, lost profits from lost sales, and reasonable royalty damages.
CRA Sessions: AI in Practice | Copyright in the age of AI: Following the evidence
A historic $1.5 billion settlement by Anthropic delivered the first significant judicial ruling on the issue. The ruling is expected to influence how courts,...